Cardiology

MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.

Palaniappan explains what steps to take in managing cardiovascular disease risk among a population that does not adhere to the Life’s Essential 8 guidelines.

Despite being considered superior to in-clinic measurements, a substantial number of patients do not follow the HBPM guideline recommendations of 12 readings per week.

Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.

A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.

Mehran addresses roadblocks to inclusivity in new drug trials, emphasizing the need for a more diverse patient population for more broadly applicable evidence.

The KAI 12L program is now cleared to determine short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

The report details the disease burden, mortality, and quality of care trends for 5 major risk factors and the 5 leading causes of CVD death.

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

Osborne discusses the background behind fenofibrates’ approval for cardiovascular event reduction, despite no evidence supporting their efficacy.

Kohli discusses the importance of the FDA’s recent label change and how clinicians can help reduce the continued prescription of ineffective medication.

Catch up with major FDA decisions, critical conference news, and more.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and CRLs, in this week’s essential news roundup.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 trial readouts, in this week's essential news roundup.

The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.